Andreas Argyrides

Vice President, Equity Research

AREA OF FOCUS

Emerging Pharmaceuticals


ANALYST BIOGRAPHY

Andreas Argyrides has covered the emerging pharmaceutical sector at Wedbush PacGrow since 2020. During this tenure, Andreas delved into a wide range of therapeutic technologies and disease areas including novel platform delivery technologies within eye, liver and lung diseases, traditional small molecules for metabolic and endocrine diseases and gene therapy for rare genomic diseases. His decade-plus experience in various roles across the healthcare industry from venture capital and investment banking to trading and equity research on the buyside gives him an integrated perspective with deep industry and scientific insight.

Andreas received his B.A. in History and Economics with honors from New York University.

ANALYST EDGE

Andreas’ Edge: With his comprehensive experience across different areas of the healthcare sector, Andreas combines a detailed perspective on the science with the intricate investing dynamics around clinical and regulatory catalysts to help investors identify opportunities for value creation. He also leverages his extensive expert network to better assess the risk/reward of clinical development as well as the market potential and growth trajectory of commercial launches.

COMPANIES UNDER COVERAGE

  • Aerovate Therapeutics (AVTE)
  • Albireo Pharma (ALBO)
  • Ascendis Pharma (ASND)
  • Aquestive Therapeutics, Inc. (AQST)
  • ARS Pharmaceuticals, Inc. (SPRY)
  • BioMarin (BMRN)
  • Clearside Biomedical (CLSD)
  • Gossamer Bio (GOSS)
  • Immunic, Inc. (IMUX)
  • Kala Pharmaceuticals (KALA)
  • Liquidia (LQDA)
  • Pacira Biosciences Inc. (PCRX)
  • Rani Therapeutics (RANI)
  • REGENXBIO Inc. (RGNX)
  • Sangamo Therapeutics (SGMO)
  • United Therapeutics (UTHR)
  • UNITY Biotechnology (UBX)
  • Verona Pharma (VRNA)